Upadacitinib (Rinvoq®) for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older, who are candidates for systemic therapy.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||05/07/2021|
|Rapid review completed||29/07/2021|
|Rapid Review outcome||A full HTA is not recommended. The NCPE recommends that upadacitinib should not be considered for reimbursement at the submitted price.*|
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.